

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Subcutaneous progesterone (Prolutex) versus vaginal (Cyclogest) for luteal phase support in IVF/ICSI cycles: a randomized controlled clinical trial study phase 3

#### Protocol summary

##### Summary

This study is planned to evaluate the efficacy and tolerability of subcutaneous administration of progesterone compared with vaginal progesterone for luteal phase support in cycles IVF / ICSI in referring patients to the Royan Institute. A randomized controlled clinical trial is conducted during 1393 to 1394 in the Royan Institute. After ovum pick up, eligible women were randomly allocated into two groups (group A and B). luteal phase support is done in two ways: subcutaneous injection of progesterone (Prolutex) and vaginal suppository. In the Group A (n = 70), since ovum pick up day, a daily subcutaneous injections of progesterone (25 mg) (Prolutex®; IBSA Institut, SA Biochimique) will be used and in the Group B (n= 70), one vaginal suppository will be used (Cyclogest ®; Actavis, Barnstaple, UK). If pregnancy is occurred it continues until 10 weeks of pregnancy. Sixteen days after embryo transfer, as well as 6 and 10 weeks of pregnancy, possible side effects (gastrointestinal, skin, and local), pain and discomfort during use of the drugs will follow by the designed questionnaire and will be recorded. Side-effect, clinical pregnancy and abortion rates will be compared between two groups by appropriate statistical tests.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201402191141N18**

Registration date: **2015-02-19, 1393/11/30**

Registration timing: **prospective**

Last update:

Update count: **0**

##### Registration date

2015-02-19, 1393/11/30

#### Registrant information

##### Name

Kiandokht Kiani

##### Name of organization / entity

Royan Institute

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 2230 7960

##### Email address

kiandokht.kiani@royaninstitute.org

#### Recruitment status

##### Recruitment complete

#### Funding source

Royan Institute and Shafayab gostar pharmaceutical company

#### Expected recruitment start date

2015-02-21, 1393/12/02

#### Expected recruitment end date

2016-01-20, 1394/10/30

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### Scientific title

Subcutaneous progesterone (Prolutex) versus vaginal (Cyclogest) for luteal phase support in IVF/ICSI cycles: a randomized controlled clinical trial study phase 3

#### Public title

Subcutaneous progesterone versus vaginal suppository for luteal phase support in assisted reproductive technology cycles in patients referred to Royan Institute

#### Purpose

Treatment

## Inclusion/Exclusion criteria

Inclusion Criteria: Female age 19–39 years ; An written consent to participate in the study ;Body mass index (BMI ) <30 kg/m<sup>2</sup> Exclusion Criteria: Severe male infertility (TESE, PESA) ; The uterine cause of infertility (uterine surgery history, cervical insufficiency, submucosal myoma or intramural fibroids ≥ 5 cm and multiple uterine polyps) ; Patients with poor ovarian response or patients with reduced ovarian reserve (FSH ≥ 15 IU/ml, AMH ≤ 1 ng/ml) ; Tubal factor was diagnosed as hydrosalpinx ; Moderate and severe endometriosis (stage3and 4) ; Cases of repeated implantation failure (RIF) and spontaneous abortions.

## Age

From **19 years** old to **39 years** old

## Gender

Female

## Phase

3

## Groups that have been masked

*No information*

## Sample size

Target sample size: **80**

## Randomization (investigator's opinion)

Randomized

## Randomization description

## Blinding (investigator's opinion)

Not blinded

## Blinding description

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Royan Institute

##### Street address

Royan Institute, Number 12, East Hafez Avenue, Bani Hashem Street, Resalat high way, Tehran, Iran

##### City

Tehran

##### Postal code

#### Approval date

2015-01-13, 1393/10/23

#### Ethics committee reference number

1102/93/EC

## Health conditions studied

### 1

#### Description of health condition studied

Other complications associated with artificial fertilization

#### ICD-10 code

N98

#### ICD-10 code description

Complications associated with artificial fertilization

## Primary outcomes

### 1

#### Description

Clinical pregnancy rate

#### Timepoint

Evidence of pregnancy by clinical (fetal heartbeat) or ultrasound parameters (ultrasound visualization of a gestational sac, embryonic pole with heartbeat)after 7-6 weeks after embryos transfer

#### Method of measurement

Vaginal sonography

### 2

#### Description

Pain during drug use

#### Timepoint

The patient records pain during drug using based on visual scale from 0 to 10

#### Method of measurement

Visual analog scale

### 3

#### Description

Comfort and satisfaction of drug

#### Timepoint

The patient records comfort and satisfaction during drug using based on visual scale from 0 to 10

#### Method of measurement

Visual analog scale

## Secondary outcomes

### 1

#### Description

Early Miscarriage rate

#### Timepoint

spontaneous loss of a pregnancy before 12 weeks

#### Method of measurement

Vaginal sonography

## Intervention groups

### 1

#### Description

Intervention: Luteal phase support during ART treatment with subcutaneous injections of progesterone (Prolutex): since ovum pick up day, a daily subcutaneous injection

of progesterone (25 mg) (Prolutex®; IBSA Institut, SA Biochimique) will be used and if pregnancy is occurred it continues until 10 weeks of pregnancy.

#### Category

Treatment - Drugs

### 2

#### Description

Control group : Luteal phase support during ART treatment using a vaginal suppository (Cyclogest) : Since ovum pick up day, one vaginal suppository every 12 hours will be used (Cyclogest ®; Actavis, Barnstaple, UK), If pregnancy is occurred it continues until 10 weeks of pregnancy.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Royan Institute

##### Full name of responsible person

Dr Moini

##### Street address

Royan Institute, Number 12, East Hafez Avenue, Bani Hashem Street, Resalat high way, Tehran, Iran

##### City

Tehran

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Royan Institute

##### Full name of responsible person

Dr.Abdolhossein Shahverdi

##### Street address

: Royan Institute, Number 12, East Hafez Avenue, Bani Hashem Street, Resalat high way, Tehran, Iran

##### City

Tehran

##### Grant name

##### Grant code / Reference number

##### Is the source of funding the same sponsor organization/entity?

Yes

##### Title of funding source

Royan Institute

##### Proportion provided by this source

##### Public or private sector

empty

##### Domestic or foreign origin

empty

##### Category of foreign source of funding

empty

##### Country of origin

#### Type of organization providing the funding

empty

### 2

#### Sponsor

##### Name of organization / entity

Shafayab Gostar company

##### Full name of responsible person

Elham Sahafi

##### Street address

275 number , after Modarres Bridge , beheshti Street.

##### City

Tehran

##### Grant name

##### Grant code / Reference number

##### Is the source of funding the same sponsor organization/entity?

Yes

##### Title of funding source

Shafayab Gostar company

##### Proportion provided by this source

##### Public or private sector

empty

##### Domestic or foreign origin

empty

##### Category of foreign source of funding

empty

##### Country of origin

##### Type of organization providing the funding

empty

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Royan Institute

##### Full name of responsible person

Dr Ashraf Moini

##### Position

Gynecologist / Professor

##### Other areas of specialty/work

##### Street address

: Royan Institute, Number 12, East Hafez Avenue, Bani Hashem Street, Resalat high way, Tehran, Iran

##### City

Tehran

##### Postal code

##### Phone

+98 21 2356 2640

##### Fax

##### Email

a\_moini@royaninstitute.org

##### Web page address

## Person responsible for scientific inquiries

#### Contact

##### Name of organization / entity

Royan Institute

##### Full name of responsible person

Dr Ashraf Moini

**Position**

Gynecologist / Professor

**Other areas of specialty/work**

**Street address**

: Royan Institute, Number 12, East Hafez Avenue,  
Bani Hashem Street, Resalat high way, Tehran, Iran

**City**

Tehran

**Postal code**

**Phone**

+98 21 2356 2640

**Fax**

**Email**

a\_moini@royaninstitute.org

**Web page address**

: Royan Institute, Number 12, East Hafez Avenue,  
Bani Hashem Street, Resalat high way, Tehran, Iran

**City**

Tehran

**Postal code**

**Phone**

+98 21 2356 2640

**Fax**

**Email**

arezoo.arabipoor@gmail.com

**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Royan Institute

**Full name of responsible person**

Arezoo Arabipoor

**Position**

M.Sc of midwifery

**Other areas of specialty/work**

**Street address**